WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018083538) ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/083538    International Application No.:    PCT/IB2017/001490
Publication Date: 11.05.2018 International Filing Date: 07.11.2017
IPC:
C07K 16/18 (2006.01), C07K 7/00 (2006.01), A61K 39/395 (2006.01), A61K 38/08 (2006.01), A61K 38/10 (2006.01)
Applicants: NEURACLE SCIENCE CO., LTD. [KR/KR]; Anam-ro 145, 702-2ho Seongbuk-gu Seoul 136-713 (KR)
Inventors: CHUNG, Jun, Ho; (KR).
YUNE, Tae Young; (KR).
KIM, Bongcheol; (KR).
SEONG, Jae, Young; (KR).
HWANG, Jong, Ik; (KR).
JIN, Jun, Yeong; (KR).
LEE, Jee, Youn; (KR).
CHO, Eun, Bee; (KR)
Priority Data:
62/418,674 07.11.2016 US
Title (EN) ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
(FR) ANTICORPS ANTI- FAMILLE AVEC SIMILARITÉ DE SÉQUENCE 19, ÉLÉMENT A5 ET LEUR PROCÉDÉ D'UTILISATION
Abstract: front page image
(EN)The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
(FR)La présente invention concerne des anticorps qui se lient spécifiquement au FAM19A5 d'origine humaine et des compositions comprenant ces anticorps. Dans un aspect spécifique, les anticorps se lient plus particulièrement au FAM19A5 d'origine humaine et modulent son activité, par exemple, inhibent, suppriment, réduisent ou neutralisent l'apparition d'une gliose réactive et/ou d'une prolifération excessive d'astrocytes réactifs, en utilisant de tels anticorps. La présente invention concerne également des procédés de traitement de troubles, tels que des lésions du système nerveux central, un trouble cérébral dégénérative, ou une douleur neuropathique, par l'administration d'un anticorps qui se lie plus particulièrement au FAM19A5 d'origine humaine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)